![Gritstone bio, Inc. logo](/logos/GRTS.webp)
Gritstone bio, Inc.
NASDAQ:GRTS
Overview | Financials
Company Name | Gritstone bio, Inc. |
Symbol | GRTS |
Currency | USD |
Price | 0.467 |
Market Cap | 55,168,714 |
Dividend Yield | 0% |
52-week-range | 0.42 - 3.33 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. |
Website | https://gritstonebio.com |
An error occurred while fetching data.
About Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD